Inflammation, immunity, and Alzheimer's disease
- PMID: 20205648
- PMCID: PMC2855399
- DOI: 10.2174/187152710791012008
Inflammation, immunity, and Alzheimer's disease
Abstract
Few topics in the field of Alzheimer's disease (AD) research have brought about the level of excitement and interest as the role of inflammation and immunity in the pathobiology and treatment of the disease. In this special issue of the journal, experts in the field give their views on how inflammatory processes and the immune system intersect- at both etiological and treatment levels- with disease biology. Collectively, nearly three decades of work are covered in this special issue, beginning with the first epidemiologic studies that showed an inverse risk relationship between AD and use of non-steroidal anti-inflammatory drugs, and ending with "immunotherapy" approaches and recent studies examining the roles of innate immune cells including microglia and peripheral mononuclear phagocytes in AD. Despite considerable work in this area, many important questions remain concerning the nature and timing of immune/inflammatory responses in the context of AD, and at what point and how to therapeutically intervene.
Similar articles
-
Re-balancing of inflammation and abeta immunity as a therapeutic for Alzheimer's disease-view from the bedside.CNS Neurol Disord Drug Targets. 2010 Apr;9(2):192-6. doi: 10.2174/187152710791012044. CNS Neurol Disord Drug Targets. 2010. PMID: 20205641 Review.
-
The role of the immune system in Alzheimer disease: Etiology and treatment.Ageing Res Rev. 2017 Nov;40:84-94. doi: 10.1016/j.arr.2017.08.005. Epub 2017 Sep 21. Ageing Res Rev. 2017. PMID: 28941639 Review.
-
Assessing activation states in microglia.CNS Neurol Disord Drug Targets. 2010 Apr;9(2):174-91. doi: 10.2174/187152710791012053. CNS Neurol Disord Drug Targets. 2010. PMID: 20205642 Review.
-
Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence.CNS Neurol Disord Drug Targets. 2010 Apr;9(2):132-9. doi: 10.2174/187152710791012026. CNS Neurol Disord Drug Targets. 2010. PMID: 20205647 Review.
-
Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator-activated receptor gamma.Curr Med Chem. 2009;16(6):643-51. doi: 10.2174/092986709787458399. Curr Med Chem. 2009. PMID: 19199928 Free PMC article. Review.
Cited by
-
Progress of Ginsenoside Rb1 in neurological disorders.Front Pharmacol. 2024 Jan 24;15:1280792. doi: 10.3389/fphar.2024.1280792. eCollection 2024. Front Pharmacol. 2024. PMID: 38327982 Free PMC article. Review.
-
Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice.Sci Rep. 2015 Jan 14;5:7771. doi: 10.1038/srep07771. Sci Rep. 2015. PMID: 25586780 Free PMC article.
-
Telomere shortening and Alzheimer's disease.Neuromolecular Med. 2013 Mar;15(1):25-48. doi: 10.1007/s12017-012-8207-9. Epub 2012 Nov 16. Neuromolecular Med. 2013. PMID: 23161153 Review.
-
Ginsenoside Rb1 improves learning and memory ability through its anti-inflammatory effect in Aβ1-40 induced Alzheimer's disease of rats.Am J Transl Res. 2019 May 15;11(5):2955-2968. eCollection 2019. Am J Transl Res. 2019. PMID: 31217866 Free PMC article.
-
From the Bush to the Brain: Preclinical Stages of Ethnobotanical Anti-Inflammatory and Neuroprotective Drug Discovery-An Australian Example.Int J Mol Sci. 2023 Jul 4;24(13):11086. doi: 10.3390/ijms241311086. Int J Mol Sci. 2023. PMID: 37446262 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical